A startup that's making 'superblood' to treat conditions like cancer just raised $100 million to get its treatments through key trials

Courtesy Rubius

• Rubius Therapeutics, a biotech developing red blood cell therapies, just raised $100 million.
• This is the second time the startup has raised money in the past year. In June 2017, Rubius raised $120 million from investors including Flagship Pioneering.
• The company is starting by developing enzyme replacement therapies for rare conditions in which the body doesn't make a particular enzyme, as well as cancer therapies that aim to re-engineer the body's immune system. 

---

Rubius Therapeutics, a startup building red blood cells that have been reprogrammed to treat conditions like cancer, just raised $100 million.  

It's the second time the startup has raised money in the past year. In June 2017, Rubius raised $120 million from investors including Flagship Pioneering. Thursday's crossover funding round included investments from mutual funds and institutional investors that weren't immediately named. 

See the rest of the story at Business Insider

NOW WATCH: Amazon is shaking up a healthcare industry that's ripe for disruption

See Also:

• We're at the beginning of 'a big new field of medicine' — and one startup just got $53 million to supercharge it
• There's a clear playbook for how Amazon could upend the healthcare business — along with an obvious victim
• A startup that wants to better understand the relationship our gut has to our brain just raised $66 million

SEE ALSO: A medical breakthrough that hacks genes to fight cancer just got approved, and it's the beginning of 'a big new field of medicine'

DON'T MISS: There's a clear playbook for how Amazon could upend the healthcare business — along with an obvious victim

from Feedburner http://ift.tt/2EZVmj4